752 P. R o b s o n
Hohmann AG, Farthing JN, Zvonok AM, Makriyannis A (2004) Selective activation of
cannabinoid CB2 receptors suppresses hyperalgesia evoked by intradermal capsaicin.
J Pharmacol Exp Ther 308:446–453
Holdcroft A, Smith M, Jacklin A, et al (1997) Pain relief with oral cannabinoids in familial
Mediterranean fever. Anaesthesia 5:483–486
Hollister LE (1971) Hunger and appetite after single doses of marihuana, alcohol, and
dextroamphetamine. Clin Pharmacol Ther 12:44–49
House of Lords Select Committee on Science and Technology (1998) Ninth Report. London
Ilaria RL, Thornby JI, Fann WE (1981) Nabilone, a cannabinoid derivative, in the treatment
of anxiety neurosis. Curr Ther Res Clin Exp 29:943–949
Institute of Medicine (1999) The medical value of marijuana and related substances. In:
Joy JE, Watson SJ, Benson JA (eds) Marijuana and medicine: assessing the science base.
National Academic Press, Washington, 137–191
Iversen L (2001) Few well controlled trials of cannabis exist for systematic review. Br Med J
323:1250
Jain AK, Ryan JR, McMahon FG, Smith G (1981) Evaluation of intramuscular levonantradol
and placebo in acute postoperative pain. J Clin Pharmacol 21:320S–326S
Jarvinen T, Pate D, Laine K (2002) Cannabinoids in the treatment of glaucoma. Pharmacol
Ther 95:203–220
Jatoi A, Windshitl HE, Loprinzi CL, et al (2002) Dronabinol versus megestrol acetate versus
combination therapy for cancer-associated anorexia. J Clin Oncol 20:567–573
Javid FA, Wright C, Naylor RJ, et al (2002) An inhibitory role for cannabinoids in the control
of motion sickness in Suncus murinus. In: Symposium on the Cannabinoids; Asilomar
Conference Center, Pacific Grove, CA. International Cannabinoid Research Society, 13
July 2002: abstr 141
Johns A (2001) Psychiatric effects of cannabis. Br J Psychiatry 178:116–122
Jones RT (2002) Cardiovascular system effects of marijuana. J Clin Pharmacol 42:58–63S
Jones RT, Benowitz NL, Herning RL (1981) Clinical relevance of cannabis tolerance and
dependence. J Clin Pharmacol 21:143S–152S
Jones SE, Durant JR, Greco FA, et al (1982) A multi-institutional phase III study of nabilone
vs placebo in chemotherapy-induced nausea and vomiting. Cancer Treat Rev 9:45–48S
Karler R, Turkanis SA (1981) The cannabinoids as potential antiepileptics. J Clin Pharmacol
21:437S–448S
Karniol IG, Carlini EA (1973) Pharmacological interaction between cannabidiol and delta-
9-THC. Psychopharmacologia 33:53–70
Karst M, Salim K, Burstein S, et al (2003) Analgesic effect of the synthetic cannabinoid CT-3
on chronic neuropathic pain: a randomised controlled trial. JAMA 290:1757–1762
Kaslow RA, Blackwelder WC, Ostrow DG, et al (1989) No evidence for a role of alcohol or
other psychoactive drugs in accelerating immunodeficiency in HIV-1-positive individ-
uals. JAMA 261:3424–3429
Keeler MH, Reifler CB (1967) Grand mal convulsions subsequent to marihuana smoking.
Dis Nerv Syst 18:474–475
Killestein J, Hoogervorst EL, Reif M, et al (2002) Safety, tolerability, and efficacy of orally
administered cannabinoids in MS. Neurology 58:1404–1407
Kirkham TC (2003) Endogenous cannabinoids: a new target in the treatment of obesity. Am
J Physiol Regul Integr Comp Physiol 284:R343–R344
Kirkham TC, Williams CM (2001) Endogenous cannabinoids and appetite. Nutr Res Rev
14:65–86
Knoller N, Levi L, Shoshan I, et al (2002) Dexanabinol (HU-211) in the treatment of severe
closed head injury: a randomised, placebo-controlled, phase II clinical trial. Crit Care
Med 30:548–554
Levitt M (1986) Cannabinoids as antiemetics in cancer chemotherapy. In: Mechoulam R
(ed) Cannabinoids as therapeutic agents. CRC Press, Boca Raton, 71–83